CAMURUS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 550.5 SEK | -1.70% |
|
-2.91% | +2.32% |
| 01:18pm | Camurus' Rare Growth Disorder Drug Accepted for Review in EU | MT |
| May. 08 | Transcript : Camurus AB, Q1 2024 Earnings Call, May 08, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 4,363 | 10,109 | 8,268 | 14,000 | 29,926 | 31,722 | - | - |
| Enterprise Value (EV) 1 | 4,032 | 9,673 | 7,882 | 13,461 | 28,760 | 29,576 | 28,445 | 26,354 |
| P/E ratio | -13.6 x | -58.6 x | -90.8 x | 260 x | 71.7 x | 93.9 x | 33.7 x | 16 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 41.3 x | 30.1 x | 13.8 x | 14.6 x | 17.4 x | 16.8 x | 10.7 x | 7.25 x |
| EV / Revenue | 38.2 x | 28.8 x | 13.1 x | 14.1 x | 16.8 x | 15.7 x | 9.58 x | 6.02 x |
| EV / EBITDA | -11.5 x | -49.9 x | -92.3 x | 159 x | 53.3 x | 66.9 x | 23.4 x | 11.9 x |
| EV / FCF | -9,345,178 x | -39,944,430 x | -53,125,507 x | 135,562,458 x | 48,194,596 x | - | 30,178,121 x | 15,237,594 x |
| FCF Yield | -0% | -0% | -0% | 0% | 0% | - | 0% | 0% |
| Price to Book | 6.91 x | 11.9 x | 9.67 x | 14 x | 20.7 x | 11.1 x | 8.93 x | 5.76 x |
| Nbr of stocks (in thousands) | 51,637 | 54,234 | 54,829 | 55,423 | 55,624 | 57,624 | - | - |
| Reference price 2 | 84.50 | 186.4 | 150.8 | 252.6 | 538.0 | 560.0 | 560.0 | 560.0 |
| Announcement Date | 2/12/20 | 2/11/21 | 2/16/22 | 2/14/23 | 2/15/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 105.6 | 336 | 601 | 956.3 | 1,717 | 1,886 | 2,969 | 4,375 |
| EBITDA 1 | -351 | -193.7 | -85.37 | 84.89 | 539.9 | 441.9 | 1,218 | 2,213 |
| EBIT 1 | -360 | -205.2 | -111 | 71.96 | 525.9 | 410.8 | 1,199 | 2,187 |
| Operating Margin | -340.91% | -61.08% | -18.47% | 7.52% | 30.63% | 21.78% | 40.37% | 49.99% |
| Earnings before Tax (EBT) 1 | -361.6 | -206.6 | -111.8 | 73.12 | 549.3 | 424.4 | 1,210 | 2,200 |
| Net income 1 | -289.9 | -167.3 | -90.45 | 55.55 | 431.4 | 349.4 | 984.5 | 1,831 |
| Net margin | -274.53% | -49.78% | -15.05% | 5.81% | 25.13% | 18.53% | 33.16% | 41.84% |
| EPS 2 | -6.230 | -3.180 | -1.660 | 0.9700 | 7.500 | 5.965 | 16.62 | 35.07 |
| Free Cash Flow | -431.4 | -242.2 | -148.4 | 99.29 | 596.8 | - | 942.6 | 1,730 |
| FCF margin | -408.56% | -72.07% | -24.69% | 10.38% | 34.76% | - | 31.75% | 39.53% |
| FCF Conversion (EBITDA) | - | - | - | 116.97% | 110.53% | - | 77.41% | 78.16% |
| FCF Conversion (Net income) | - | - | - | 178.74% | 138.32% | - | 95.74% | 94.48% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/12/20 | 2/11/21 | 2/16/22 | 2/14/23 | 2/15/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 183 | 220.3 | 226.7 | 241.4 | 268 | 284 | 674.3 | 384 | 374.6 | 390 | 444.3 | 492.7 | 606.9 |
| EBITDA 1 | -10.1 | 7.928 | 10.04 | 44.28 | 22.64 | 77.6 | 379.4 | 107.5 | -24.65 | 82.35 | 84.92 | 113.7 | 227.1 |
| EBIT 1 | -18 | 4.791 | 6.915 | 41.37 | 18.88 | 74.34 | 376.1 | 104 | -28.54 | 78.66 | 81.43 | 110.2 | 223.6 |
| Operating Margin | -9.84% | 2.17% | 3.05% | 17.14% | 7.04% | 26.17% | 55.77% | 27.1% | -7.62% | 20.17% | 18.33% | 22.37% | 36.84% |
| Earnings before Tax (EBT) 1 | -18.44 | 4.498 | 6.622 | 41.51 | 20.49 | 76.87 | 380.6 | 109.8 | -18.01 | 96.86 | 94.65 | 112.6 | 153.9 |
| Net income 1 | -14.02 | -0.752 | 8.239 | 35 | 13.07 | 58.83 | 301.4 | 86.4 | -15.21 | 77.86 | 66.14 | 89.08 | 179.2 |
| Net margin | -7.66% | -0.34% | 3.63% | 14.5% | 4.88% | 20.71% | 44.7% | 22.5% | -4.06% | 19.97% | 14.89% | 18.08% | 29.53% |
| EPS 2 | -0.2600 | -0.0100 | 0.1400 | 0.6100 | 0.2300 | 1.020 | 5.240 | 1.500 | -0.2700 | 1.320 | 1.119 | 1.507 | 3.032 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/16/22 | 5/12/22 | 7/15/22 | 11/10/22 | 2/14/23 | 5/10/23 | 7/18/23 | 11/9/23 | 2/15/24 | 5/8/24 | - | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 331 | 436 | 386 | 539 | 1,165 | 2,146 | 3,277 | 5,368 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -431 | -242 | -148 | 99.3 | 597 | - | 943 | 1,730 |
| ROE (net income / shareholders' equity) | -65.6% | -22.6% | -10.7% | 6.03% | 34.7% | 18.4% | 37% | 48.7% |
| ROA (Net income/ Total Assets) | - | -18.4% | -8.51% | 4.65% | 26.9% | 10.3% | 37.6% | 42.4% |
| Assets 1 | - | 908.1 | 1,063 | 1,194 | 1,607 | 3,386 | 2,615 | 4,317 |
| Book Value Per Share 2 | 12.20 | 15.60 | 15.60 | 18.10 | 26.00 | 50.40 | 62.70 | 97.20 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 4.63 | 3.33 | 4.94 | 1.91 | 10.1 | 40.7 | 17.8 | 26.1 |
| Capex / Sales | 4.39% | 0.99% | 0.82% | 0.2% | 0.59% | 2.16% | 0.6% | 0.6% |
| Announcement Date | 2/12/20 | 2/11/21 | 2/16/22 | 2/14/23 | 2/15/24 | - | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
560
SEK
Average target price
593.2
SEK
Spread / Average Target
+5.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.32% | 3.01B | |
| +38.69% | 723B | |
| +34.28% | 595B | |
| -4.49% | 369B | |
| +20.24% | 332B | |
| +2.12% | 282B | |
| +17.02% | 244B | |
| +9.31% | 208B | |
| -5.07% | 205B | |
| -0.35% | 168B |
- Stock Market
- Equities
- CAMX Stock
- Financials Camurus AB
